First time in Human Study of AZD8701 with or without Durvalumab in Participants with Advanced Solid Tumours

Exclusion Criteria

• - A condition that, in the opinion of the Investigator, would interfere with evaluation of the study intervention or interpretation of participant safety or study results
• - History of allogeneic organ transplantation.
• - Active or prior documented autoimmune or inflammatory disorders
• Uncontrolled intercurrent illness
• - Significant cardiac disease
• - History of another primary malignancy except for
• (a) Malignancy treated with curative intent and with no known active disease ≥ 5 years
• (b) non-melanoma skin cancer
• (c) Adequately treated carcinoma in situ without evidence of disease.
• - Participant with previous or confirmed Covid 19 diagnosis requiring significant medical intervention
• - Current clinical signs and symptoms consistent with COVID-19 or confirmed current infection by appropriate laboratory test within the last 4 weeks prior to screening
• - Any major unresolved toxicity from previous anticancer therapy
• - Known allergy or hypersensitivity to any of the study interventions or any of the study intervention excipients.
• Prior/Concomitant Therapy
• - Receipt of the last dose of anticancer therapy within 5 half-lives or ≤ 21 days prior to the first dose of study
• - Prior treatment with potential Treg depletion therapies including agents targeting OX40 or CD357 (GITR) for 90 days prior to enrolment on study.
• - Participants who have received prior anti-PD-1, anti-PD-L1, or anti-CTLA-4:
• (a) Must not have experienced a toxicity that led to permanent discontinuation of prior
• immunotherapy.
• (b) All AEs while receiving prior immunotherapy must have completely resolved or
• resolved to baseline
• (c) Must not have experienced a ≥ Grade 3 imAE or a neurologic or ocular imAE of any grade while receiving prior immunotherapy.
• (d) Must not have required the use of additional immunosuppression other than corticosteroids for the management of an AE
• - Current or prior use of immunosuppressive medication within 14 days before the first dose of study drug. b. The following are exceptions to this criterion:
• (a) Intranasal, inhaled, topical steroids, or local steroid injections (eg, intra-articular injection).
• (b) Systemic corticosteroids at physiologic doses not to exceed 10 mg/day of prednisone or its equivalent
• (c) Steroids as premedication for hypersensitivity reactions (eg, CT scan premedication)
• - Any concurrent chemotherapy, investigational product, biologic, or hormonal therapy for
• cancer treatment
• - Radiotherapy treatment to more than 30% of the bone marrow or with a wide field of radiation within 4 weeks of the first dose of study intervention.
• - Major surgical procedure within 28 days prior to the first
• dose
• - Participants receiving anticoagulation therapy with vitamin K antagonists (eg warfarin)
• - Participation in another clinical study with study intervention administered in the last 30 days
• -Female participants who are pregnant or breastfeeding or male and female participants of reproductive potential who are not willing to employ effective birth control